JP2021505200A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505200A5
JP2021505200A5 JP2020550047A JP2020550047A JP2021505200A5 JP 2021505200 A5 JP2021505200 A5 JP 2021505200A5 JP 2020550047 A JP2020550047 A JP 2020550047A JP 2020550047 A JP2020550047 A JP 2020550047A JP 2021505200 A5 JP2021505200 A5 JP 2021505200A5
Authority
JP
Japan
Prior art keywords
seq
znf274
targeting system
snrpn
dna targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020550047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/064517 external-priority patent/WO2019113472A1/en
Publication of JP2021505200A publication Critical patent/JP2021505200A/ja
Publication of JP2021505200A5 publication Critical patent/JP2021505200A5/ja
Pending legal-status Critical Current

Links

JP2020550047A 2017-12-08 2018-12-07 ゲノムインプリンティングの障害を治療するための組成物及び方法 Pending JP2021505200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762596397P 2017-12-08 2017-12-08
US62/596,397 2017-12-08
PCT/US2018/064517 WO2019113472A1 (en) 2017-12-08 2018-12-07 Compositions and methods for treating disorders of genomic imprinting

Publications (2)

Publication Number Publication Date
JP2021505200A JP2021505200A (ja) 2021-02-18
JP2021505200A5 true JP2021505200A5 (https=) 2022-01-11

Family

ID=66750623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550047A Pending JP2021505200A (ja) 2017-12-08 2018-12-07 ゲノムインプリンティングの障害を治療するための組成物及び方法

Country Status (6)

Country Link
US (1) US12018255B2 (https=)
EP (1) EP3720508A4 (https=)
JP (1) JP2021505200A (https=)
AU (1) AU2018380422A1 (https=)
CA (1) CA3084810A1 (https=)
WO (1) WO2019113472A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
KR102787119B1 (ko) 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
WO2019168950A1 (en) * 2018-02-27 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for treating angelman syndrome
US20220364124A1 (en) * 2019-10-02 2022-11-17 Duke University Epigenetic modulation of genomic targets to control expression of pws-associated genes
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
JPWO2008084319A1 (ja) * 2006-12-18 2010-04-30 協和発酵キリン株式会社 新規核酸
GB0718542D0 (en) * 2007-09-22 2007-10-31 Univ Dundee Targeted modulation of gene expression
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US20180305689A1 (en) 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2021505200A5 (https=)
KR102867099B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
IL325248A (en) Oligonucleotides for inducing paternal ube3a expression
JP2018536689A5 (https=)
JP2018529732A5 (https=)
IL317818A (en) Oligonucleotides to reduce PD-L1 expression
JP2019531763A5 (https=)
JP2018533954A5 (https=)
JP2022519882A5 (https=)
JP2016502858A5 (https=)
JP2020517653A5 (https=)
BR9708701A (pt) Inibidores anti-sense de expressão do fator de crescimento endotelial vascular.
JP2015532097A5 (https=)
JP2022533358A5 (https=)
JP2021500016A5 (https=)
JP2010259439A5 (https=)
WO2000009525A3 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
JP2019533472A5 (https=)
MX420940B (es) Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
JP2019517262A5 (https=)
EP1758998A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES
US20180296635A1 (en) Protein Particles Comprising Disulfide Crosslinkers and Uses Related Thereto
JP2022548800A5 (https=)
JP2020521491A5 (https=)
JP2011505798A5 (https=)